Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safety of clevidipine in the treatment of
perioperative hypertension. Approximately 500-900 patients with perioperative hypertension
undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or
minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve
replacement/repair procedures were anticipated to be randomly assigned to one of two
treatment groups: clevidipine or nitroglycerin.